Patients

This study is a retrospective study. In total, 240 are advanced LSCC patients, 196 of whom had complete medical information and follow-up in Nanjing Brain Hospital from February 2020 to December 2021 (Figure 1). Patients with advanced LSCC were stratified into two groups, docetaxel plus nedaplatin (DN) group (96 cases) and the docetaxel plus carboplatin (DC) group (100 cases). Inclusion criteria are as follows: LSCC diagnosed by histopathology; Stage IIIB and IV patients who progressed after first-line chemotherapy; response was assessed according to response assessment criteria for solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1); there were measurable target lesions before treatment; the systemic functional status score of the Eastern Cooperative Oncology Group performance status (ECOG PS) was 0–2; blood routine, hepatic, renal, or bone marrow functions were basically normal; life expectancy no shorter than 3 months; and patients completed at least 2 cycles of chemotherapy.

Flow of patients in the study.

The study was approved by the Ethics Committee of Affiliated Nanjing Chest Hospital, Nanjing Medical University (NJXK202026), Nanjing, China. All patients provided written informed consent before enrollment.